25 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 25 of 25 clinical reviews.
Everything patients and clinicians need to know about safely restarting semaglutide 2.4 mg (Wegovy) after an acute illness interruption, including dose re-escalation schedules, monitoring parameters, and evidence-based decision points.
A physician-reviewed guide to using semaglutide 2.4 mg (Wegovy) after bariatric surgery, covering clinical evidence, dosing, safety, and when it is appropriate to prescribe.
A physician-reviewed guide to semaglutide 2.4 mg (Wegovy) use in patients with autoimmune conditions, covering immune-pathway effects, disease-specific evidence, monitoring protocols, and prescribing considerations.
A clinician-level review of how semaglutide 2.4 mg (Wegovy) affects sexual function in men and women, covering direct GLP-1 receptor mechanisms, indirect weight-loss effects, testosterone changes, and what to expect at each phase of treatment.
A physician-level review of semaglutide 2.4 mg (Wegovy) and kidney outcomes, covering the FLOW trial, STEP-1 data, GFR changes, proteinuria, and how to dose-adjust in CKD.
A clinician-level review of how Wegovy (semaglutide 2.4 mg) changes appetite, cravings, and food-seeking behavior, with primary-literature citations from STEP-1 and related trials.
A clinician-level review of how semaglutide 2.4 mg (Wegovy) affects bone mineral density, fracture risk, and bone turnover markers, with citations from STEP-1, SURMOUNT trials, and current endocrine guidelines.
A physician-level review of every cancer signal linked to semaglutide 2.4 mg (Wegovy), covering thyroid, pancreatic, colorectal, and other tumor types, with primary-literature citations and clinical guidance.
A clinician-level review of semaglutide 2.4 mg (Wegovy) and its long-term cardiovascular effects, covering SELECT trial data, mechanisms, risk stratification, and prescribing guidance.
A clinical review of semaglutide 2.4 mg (Wegovy) and cognitive function, covering trial data, proposed mechanisms, safety signals, and what patients and providers need to know.
A physician-reviewed breakdown of compounded vs branded Wegovy (semaglutide 2.4 mg), covering efficacy data, safety, regulatory status, cost, and how to choose between them.
A physician-level review of the semaglutide 2.4 mg (Wegovy) evidence base, with every major outcome rated by GRADE certainty, primary-literature citations, and a practical prescribing framework.
A physician-reviewed deep dive into semaglutide 2.4 mg (Wegovy) effects on hair loss, skin laxity, and dermatological side effects, with primary-literature citations and clinical guidance.
A clinician-level review of how Wegovy (semaglutide 2.4 mg) affects liver enzymes, hepatic fat, MASLD, and fibrosis markers, with primary-literature citations and dosing guidance.
A physician-reviewed deep dive into how semaglutide 2.4 mg (Wegovy) affects mood, depression, anxiety, suicidality risk, and quality of life, with primary-literature citations and clinical guidance.
A clinician-level review of how Wegovy (semaglutide 2.4 mg) affects resting energy expenditure, thermogenesis, fat oxidation, and adaptive thermogenesis, with primary-literature citations and real dose data.
A physician-reviewed deep-dive into Wegovy (semaglutide 2.4 mg) microdosing protocols, what clinical trials say, how off-label dose adjustments are being used, and when a non-standard titration might be appropriate.
Semaglutide 2.4 mg (Wegovy) drives substantial fat loss, but up to 39% of weight lost can be lean mass. This clinical guide covers evidence-based protein, resistance training, and dosing strategies to protect muscle during GLP-1 therapy.
Why weight loss stalls on Wegovy (semaglutide 2.4 mg), how clinicians diagnose true non-response versus expected adaptation, and the evidence-based interventions that can restart progress.
A physician-reviewed guide to the Wegovy (semaglutide 2.4 mg) pre-surgery hold window, covering aspiration risk, gastric emptying data, society guidelines, and the dose-restart protocol after surgery.
Stopping Wegovy (semaglutide 2.4 mg) typically causes rapid weight regain. Learn exactly how much weight returns, why it happens, and what evidence-based strategies can slow or prevent rebound.
A clinical deep-dive into how seasonal factors, including heat, holidays, activity shifts, and injection-site changes, affect semaglutide 2.4 mg (Wegovy) therapy, with evidence-based guidance on dose timing, storage, and monitoring adjustments.
A physician-reviewed deep dive into how Wegovy (semaglutide 2.4 mg) affects sleep architecture, OSA severity, slow-wave sleep, REM cycles, and next-generation GLP-1 sleep research.
MD/PharmD-level guide to managing Wegovy (semaglutide 2.4 mg) injection timing, cold-chain storage, and dose adjustments across time zones. Includes specific day-range rules, airport security tips, and nausea management while traveling.
A clinician-reviewed, week-by-week guide to the first four weeks on Wegovy (semaglutide 2.4 mg), covering dose titration, side effects, early weight changes, and practical strategies backed by primary trial data.